Introduction
============

Colorectal cancer (CRC) is one of the most common types of cancer in Korea and other developed countries ([@b1-ol-0-0-9264],[@b2-ol-0-0-9264]). The carcinogenesis of CRC is driven by genetic and epigenetic changes in tumor cells and is also influenced by tumor-host interactions ([@b3-ol-0-0-9264]--[@b5-ol-0-0-9264]). Previous studies have reported the potential association of molecular markers such as BRAF, KRAS, and MMR with prognosis in patients with CRC ([@b6-ol-0-0-9264],[@b7-ol-0-0-9264]). Identification of the predictors of poor prognosis and disease recurrence is important for the successful treatment of these patients and for the discovery of new therapeutic strategies.

Analysis of host immunity against human malignancy is increasingly important in cancer research and treatment ([@b8-ol-0-0-9264],[@b9-ol-0-0-9264]). Immune checkpoints represent a major defense system of the tumor against antitumor immunity in the host and play an important role in suppressing the T-cell-mediated immune response in the tumor microenvironment ([@b9-ol-0-0-9264],[@b10-ol-0-0-9264]). Programmed cell death ligand-1 (PD-L1) expression in tumor cells suppresses the cytotoxic activity of CD8-positive T-cells ([@b11-ol-0-0-9264]--[@b13-ol-0-0-9264]). Up-regulation of PD-L1 has been reported in malignancies including lung cancer, esophageal cancer, renal cell carcinoma, ovarian cancer, CRC, and breast cancer and may play a central role in tumor-immune system interactions ([@b14-ol-0-0-9264]--[@b19-ol-0-0-9264]).

PD-L1 expression in tumor cells may be linked to a weakened host immune response, resulting in immune escape and an adverse prognosis in several malignancies ([@b20-ol-0-0-9264]--[@b22-ol-0-0-9264]). However, the prognostic role of PD-L1 expression in CRC is less clear, with some studies reporting conflicting results as to whether PD-L1 expression indicates a better or worse prognosis. The prognostic evaluation in these studies has been limited because they included patients at various disease stages and different study populations ([@b23-ol-0-0-9264]--[@b27-ol-0-0-9264]). The aim of this study was to evaluate the correlation between PD-L1 expression and long-term oncologic outcomes in CRC.

Materials and methods
=====================

### Patients

Formalin-fixed paraffin-embedded block specimens from surgical resection of the primary tumor were obtained from 175 patients with CRC who underwent curative surgery and adjuvant chemotherapy at our institution between September 1999 and August 2004. Baseline clinicopathological characteristics and clinical outcome data were retrospectively collected from the Colorectal Cancer Database of the Department of Colorectal Cancer Surgery and the Pathological Diagnosis Database in the Department of Pathology. The study physicians reviewed all medical records related to CRC, extracted clinical information including the American Joint Committee on Cancer tumor, node, metastases (TNM) classification, the numbers of positive and negative lymph nodes harvested and tumor location, and determined cause of death in deceased individuals.

### Production of tissue microarray block

Formalin-fixed, paraffin-embedded tissue samples were produced for tissue microarray (TMA). Representative areas of each tumor were marked on each hematoxylin and eosin-stained slide and the corresponding area of the tissue blocks was sampled. The designated area of each donor block was collected using a tissue cylinder punch (3 mm diameter), and the samples were transferred to a recipient block.

### Immunohistochemistry

Sections (4 µm thickness) from the TMAs were cut in 10% formalin buffer, embedded in paraffin, mounted onto Superfrost Plus glass slides (VWR Scientific, West Chester, PA, USA), and incubated at 60°C for 15 min. The slides were deparaffinized in xylene, rehydrated in graded alcohol solutions, and washed in tap water. Endogenous peroxidase activity was blocked by the addition of 3% H~2~O~2~. The slides were placed in a steam cooker filled with 10 mM sodium citrate buffer (pH 6.0) for antigen retrieval after treatment with a blocking agent (DAKO, Carpinteria, CA, USA) for 10 min to block nonspecific protein binding. Immunohistochemistry for antigen (PD-L1) was performed using an autostainer (LV360-2D; LabVision Co., Fremont, CA, USA). Reagents and the secondary antibody from the commercial LP Kit (TL-125-HD, LabVision Co.) were used as provided by the manufacturer. The primary antibody was a rabbit polyclonal antibody against PD-L1 (1:400, Anti-PD-L1; AnaSpec, Fremont, CA, USA). Immunopositivity was evaluated by determining the proportions of positive cells (low, ≤50%; and high, \>50%).

### Evaluation parameters

The sixth edition of the American Joint Committee on Cancer (AJCC) classification system was used to determine the pathological tumor depth (pT), the number of metastasized lymph nodes (pN), and cancer stage. A postoperative clinical examination, measurement of serum carcinoembryonic antigen CEA levels, chest radiography every 3 months, and chest/abdominal computed tomography (CT) every 6 months were performed during each follow-up examination over a period of 3 years. After 3 years, the follow-up interval was changed to 6 months. Recurrence was defined as the presence of radiologically confirmed or histologically proven tumor and the location of recurrence was defined as the first site of recurrence after complete resection. Local recurrence was defined as any tumor recurrence in the surgical field; local recurrence with synchronous systemic recurrence was included systemic recurrence. The overall survival (OS) time was defined as the time from the date of surgery to the date of the latest follow-up visit or the date of death due to any cause, while the disease-free survival (DFS) time was defined as the time from surgery to any type of recurrence.

### Statistical analyses

Data were expressed as medians with ranges. Differences in clinicopathological features between low and high-intensity PD-L1-positive CRCs were analyzed by Chi-square or Fisher\'s exact tests for categorical variables and Student\'s t-test for continuous variables. Survivals rate were determined using the Kaplan-Meier method and log-rank tests were used to compare survival rates among subgroups. Log-rank tests were also used for univariate analysis and independent prognostic factors were identified by multivariate analysis using the Cox proportional hazards model to calculate hazard ratios. All statistical tests were performed using IBM SPSS Statistics for Windows, v.21.0 (IBM Corp., Armonk, NY, USA). P\<0.05 was considered to indicate a statistically significant difference.

### Ethical statement

The study was approved by the Institutional Review Board of Keimyung University and Donsan Medical Center (IRB no. 2017-11-037) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results
=======

### Patient and tumor characteristics

PD-L1 expression was categorized as low in 82 (46.9%) patients and high in 93 (53.1%) patients ([Fig. 1](#f1-ol-0-0-9264){ref-type="fig"}). The patient and tumor characteristics of the study cohort stratified by PD-L1 status are shown in [Table I](#tI-ol-0-0-9264){ref-type="table"}. The demographic characteristics were similar between the two cohorts for age, sex, preoperative carcinoembryonic antigen level, tumor stage, nodal stage, TNM stage, histology, lymphovascular invasion, and perinodal extension. There was a trend in tumors to be located in the right-sided colon, although without statistical significance, in the high PD-L1 expression group compared to the low PD-L1 expression group (22.6 vs. 12.2%, P=0.073).

### Oncologic outcomes and recurrence pattern according to PD-L1 expression

During the median follow-up period of 88 months (range 1--196 months), the total numbers of deaths and relapse events were 102 and 57, respectively. The 10-year OS and DFS rates were significantly higher in the high PD-L1 expression group than in the low PD-L1 expression group (OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021) ([Fig. 2](#f2-ol-0-0-9264){ref-type="fig"}). According to the TNM stage subgroups, the OS rates in the low and high PD-L1 expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011), and 9.1 and 0% in stage IV (P=0.005). The DFS rates in the low and high PD-L1 expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 19.6 and 38.3% stage III (P=0.006), and 9.1 and 0% in stage IV (P=0.700). The numbers of involved organs in recurrence did not differ between groups (P=0.418; [Table II](#tII-ol-0-0-9264){ref-type="table"}). The local recurrence rate was 6.1% in the low PD-L1 expression group and 7.5% in the high PD-L1 expression group. The sites of local recurrence in the low and high PD-L1 expression groups included the anastomotic site (1.2 vs. 2.2%, P=0.636), perirectum (6.1 vs. 6.5%, P=0.923), and pelvic cavity (3.7 vs. 1.1%, P=0.254). The systemic recurrence rate was significantly higher in the low PD-L1 expression group than in the high PD-L1 expression group (42.7 vs. 12.9%, respectively, P=0.030). The sites of systemic recurrence most commonly affected in the low and high PD-L1 expression groups included the liver (25.6 vs. 7.5%, P=0.001), followed by the lungs (6.1 vs. 3.2%, P=0.364), peritoneum (3.7 vs., 2.2%, P=0.550), extraregional lymph nodes (3.7 vs. 2.2%, P=0.550), abdominal wall (1.2 vs. 0%, P=0.286), adrenal glands (1.2 vs. 0%, P=0.286), ureters (1.2 vs. 0%, P=0.286), ovaries (1.2 vs. 0%, P=0.286), and supraclavicular lymph nodes (1.2 vs. 0%, P=0.286).

### Univariate and multivariate survival analyses of prognostic factors

Univariate analyses revealed that T-stage (P=0.005 and P=0.004, respectively), N-stage (P=0.001 and P\<0.001, respectively), tumor differentiation (P=0.011 and P=0.014, respectively), lymphovascular invasion (P=0.005 and P=0.006, respectively), PD-L1 expression (P=0.047 and P=0.021, respectively), and perinodal extension (P\<0.001 and P\<0.001, respectively) were significantly associated with OS and DFS ([Table III](#tIII-ol-0-0-9264){ref-type="table"}) ([Fig. 3](#f3-ol-0-0-9264){ref-type="fig"}). Multivariate analysis found that T-stage \[hazard ratio (HR), 1.888; 95% confidence interval \[CI\], 1.022--3.488, P=0.042\] and perinodal extension (HR, 2.927; 95% CI, 1.693--5.060, P\<0.001) were independent prognostic factors for OS and PD-L1 expression (HR, 1.586; 95% CI, 1.069--2.353, P=0.022), while T-stage (HR, 1.903; 95% CI, 1.033--3.508, P=0.039) and perinodal extension (HR, 3.057; 95% CI, 1.776--5.259, P\<0.001) were independent prognostic factors for DFS ([Table IV](#tIV-ol-0-0-9264){ref-type="table"}).

Discussion
==========

PD-L1 expression has been reported in tumor cells or tumor-infiltrating immune cells in several malignancies, including CRC, and may play a central role in immune-oncologic interactions ([@b19-ol-0-0-9264],[@b28-ol-0-0-9264],[@b29-ol-0-0-9264]). The present study examined the effects of PD-L1 expression on long-term oncologic outcomes and recurrence patterns among patients with CRC. We found that PD-L1 expression was significantly associated with tumor recurrence and poor prognosis and was an independent prognostic factor for DFS, especially in stage III CRC. Moreover, the systemic recurrence rate was significantly higher and hepatic recurrence was more common in the low group than in the high expression group.

Previous studies have reported conflicting results as to whether PD-L1 expression indicates a better or worse prognosis in CRC, possibly due to differences in study populations and designs ([@b21-ol-0-0-9264],[@b23-ol-0-0-9264],[@b30-ol-0-0-9264]). In the present study, the prognostic impact of PD-L1 expression on long-term oncologic outcomes in CRC differed according to the TNM stage. In early stages, including stages I and II, there was no significant between-group difference; however, the long-term oncologic outcomes of patients with stage III disease was significantly better in the high PD-L1 expression group. In this context, our results underscore the specificities of tumor immune system interactions and microenvironments in CRC according to disease stage.

Our evaluation of the recurrence patterns according to the PD-L1 expression status revealed a significantly higher systemic recurrence rate in the low PD-L1 expression group than that in the high PD-L1 expression group. Moreover, low PD-L1 expression was significantly associated with hepatic recurrence. The high systemic recurrence rate and significant association with hepatic recurrence in the low PD-L1 expression group may be reflected in the poor prognosis.

CRC with MMR defects shows high microsatellite instability (MSI) and accounts for 12 to 15% of colorectal carcinomas. These tumors are infiltrated by higher numbers of lymphocytes and are characterized by a more favorable prognosis compared to those in MMR-proficient tumors. Some studies have reported different impacts of PD-L1 expression on survival according to microsatellite status. Dunne *et al* ([@b26-ol-0-0-9264]) demonstrated that PD-L1 expression was associated with a significantly worse recurrence-free survival in mismatch-repair-deficient tumors, whereas PD-L1 expression did not show a statistically significant association with recurrence-free survival in mismatch-repair-proficient tumors. In contrast, Droeser *et al* ([@b23-ol-0-0-9264]) reported that high PD-L1 expression in mismatch-repair-proficient CRC was associated with early tumor stage, absence of lymph node metastases, lower tumor grade, absence of vascular invasion, high numbers of tumor-infiltrating CD8+ T cells, and an improved 5-year survival rate. Unfortunately, we did not evaluate the status of germline mutations in *MLH1, MSH2, MSH6*, and *PMS2*; thus, further studies are needed to assess the possible association between MSI status and PD-L1 expression in tumor cells.

Adjuvant chemotherapy has an established role in patients with stage III and high-risk stage II CRC; however, its use remains controversial in stage II disease due to its restriction to a small subgroup of patients with high-risk prognostic factors. Dunne *et al* ([@b26-ol-0-0-9264]) used relapse follow-up data to find that patients with high PD-L1 expression had a significantly better outcome than that in patients with low expression in the untreated stage III population; however, the correlation between survival and high PD-L1 expression was lost in the stage III patients treated with adjuvant chemotherapy. They suggested that patients with high PD-L1 expression should not be administered 5-FU-based adjuvant chemotherapy following surgery. However, neither high nor low PD-L1 expression showed a statistically significant association with recurrence-free survival in our study, regardless of adjuvant chemotherapy (data not shown).

Our study has several limitations, including the small number of patients, its retrospective nature, and the lack of investigation of other immune-oncologic biomarkers such as MSI status, K-ras and BRAF mutations, and the expression of other immune checkpoints in tumor and immune cells. Further studies are needed to determine the possible association of MSI status with immune checkpoint molecules in tumor and immune cells in different stages or statuses.

Analysis of our long-term data indicates that love PD-L1 expression is significantly associated with tumor relapse and poor prognosis in CRC.
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![(A) High (52.8%) and (B) low (47.2%) PD-L1 expression.](ol-16-04-5214-g00){#f1-ol-0-0-9264}

![Ten-year overall and disease-free survival of patients with CRC according to PD-L1 expression. The 10-year OS and DFS rates were significantly higher in the high PD-L1 expression group than in the low PD-L1 expression group and low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC. CRC, colorectal cancer.](ol-16-04-5214-g01){#f2-ol-0-0-9264}

![Ten-year overall and disease-free survival of patients with CRC according to prognostic variables with statistical significance. Univariate analyses revealed that T-stage, N-stage, tumor differentiation, lymphovascular invasion, PD-L1 expression, and perinodal extension were significantly associated with overall and disease-free survival. CRC, colorectal cancer.](ol-16-04-5214-g02){#f3-ol-0-0-9264}

###### 

Characteristics of patients with CRC according to programmed death-ligand 1 status.

  Characteristics                            Low expression (N=82)   High expression (N=93)   P-value
  ------------------------------------------ ----------------------- ------------------------ ---------
  Age (years), median (range)                67 (32--86)             70 (39--100)             0.310
  Sex, n (%)                                                                                  0.711
    Male                                     48 (58.5)               57 (61.3)                
    Female                                   34 (41.5)               36 (38.7)                
  Preoperative CEA (ng/ml), median (range)   2.82 (0.3--416.8)       3.50 (0.1--332.8)        0.762
  Tumor location, n (%)                                                                       0.073
    Right side                               10 (12.2)               21 (22.6)                
    Left side                                72 (87.8)               72 (77.4)                
  Tumor stage, n (%)                                                                          0.325
    T1                                       0 (0)                   2 (2.2)                  
    T2                                       11 (13.4)               18 (19.4)                
    T3                                       64 (78.0)               68 (73.1)                
    T4                                       7 (8.5)                 5 (5.4)                  
  Nodal stage, n (%)                                                                          0.109
    N0                                       36 (43.9)               46 (49.5)                
    N1                                       20 (24.4)               30 (32.3)                
    N2                                       26 (31.7)               17 (18.3)                
  TNM stage, n (%)                                                                            0.100
    Stage I                                  6 (7.3)                 15 (16.1)                
    Stage II                                 30 (36.6)               30 (32.3)                
    Stage III                                35 (42.7)               43 (46.2)                
    Stage IV                                 11 (13.4)               5 (5.4)                  
  Histology, n (%)                                                                            0.184
    Well-differentiated                      4 (4.9)                 4 (4.3)                  
    Moderately differentiated                67 (81.3)               84 (90.3)                
    Poorly differentiated                    8 (9.8)                 2 (2.2)                  
    Mucinous                                 3 (3.7)                 3 (3.2)                  
  Lymphovascular invasion, n (%)             61 (74.4)               64 (68.8)                0.415
  Perinodal extension, n (%)                 15 (18.3)               10 (10.8)                0.155
  Recurrence pattern, n (%)                                                                   0.199
    Local recurrence                         7 (18.4)                7 (38.9)                 
    Systemic recurrence                      28 (73.7)               9 (50.0)                 
    Local and systemic recurrence            3 (7.9)                 2 (8.9)                  

CRC, colorectal cancer; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.

###### 

Recurrence patterns according to programmed death-ligand 1 expression.

  Variables                                                                 Low expression (N=82)   High expression (N=93)   P-value
  ------------------------------------------------------------------------- ----------------------- ------------------------ ---------
  Nο. of involved organs                                                                                                     0.418
    1                                                                       35 (42.7)               15 (16.1)                
    2                                                                       4 (4.9)                 4 (4.3)                  
    3                                                                       1 (1.2)                 0 (0)                    
  Recurrence pattern                                                                                                         0.030
    Local recurrence                                                        5 (6.1)                 7 (7.5)                  
    Anastomotic site                                                        1 (1.2)                 2 (2.2)                  0.636
    Perirectum                                                              5 (6.1)                 6 (6.5)                  0.923
    Pelvic cavity                                                           3 (3.7)                 1 (1.1)                  0.254
  Systemic recurrence                                                       35 (42.7)               12 (12.9)                
    Liver                                                                   21 (25.6)               7 (7.5)                  0.001
    Lung                                                                    5 (6.1)                 3 (3.2)                  0.364
    Peritoneum                                                              3 (3.7)                 2 (2.2)                  0.550
    Extraregional lymph node^[a](#tfn2-ol-0-0-9264){ref-type="table-fn"}^   3 (3.7)                 2 (2.2)                  0.550
    Abdominal wall                                                          1 (1.2)                 0 (0)                    0.286
    Adrenal gland                                                           1 (1.2)                 0 (0)                    0.286
    Ureter                                                                  1 (1.2)                 0 (0)                    0.286
    Ovary                                                                   1 (1.2)                 0 (0)                    0.286
    Supraclavicular lymph node                                              1 (1.2)                 0 (0)                    0.286

The extraregional lymph node includes the para-aortic and lateral pelvic lymph node.

###### 

Prognostic factors of survival in univariate analysis.

  Prognostic factor                      No. (n=175)   OS (%)   P-value   DFS (%)   P-value
  -------------------------------------- ------------- -------- --------- --------- ---------
  Age (years)                                                   0.554               0.466
    ≤60                                  47            48.9               48.9      
    \>60                                 128           38.0               33.8      
  Sex                                                           0.173               0.130
    Male                                 105           37.1               33.1      
    Female                               70            46.8               46.8      
  Location                                                      0.916               0.747
    Right-sided                          31            41.9               41.9      
    Left-sided                           144           40.9               37.2      
  Tumor stage                                                   0.005               0.004
    T1 and T2                            31            59.9               59.8      
    T3 and T4                            144           37.0               34.2      
  Nodal stage                                                   0.001               \<0.001
    N0                                   82            51.8               51.8      
    N1 and N2                            93            31.9               25.5      
  Histology                                                     0.011               0.014
    Well and moderately differentiated   159           43.4               40.0      
    Poorly differentiated and mucinous   16            18.8               18.8      
  Lymphovascular invasion                                       0.005               0.006
    No                                   51            56.8               56.8      
    Yes                                  124           34.6               31.4      
  PD-L1 expression                                              0.047               0.021
    Low                                  82            32.9               32.9      
    High                                 93            48.2               43.3      
  Perinodal extension                                           \<0.001             \<0.001
    No                                   150           46.6               43.3      
    Yes                                  25            12                 8         

DFS, disease-free survival; OS, overall survival; PALN, para-aortic lymph node; PreOP CEA, preoperative carcinoembryonic antigen; PD-L1, programmed death-ligand 1.

###### 

Prognostic factors of survival in multivariate analysis.

                                                                                Overall survival       Disease-free survival                          
  ----------------------------------------------------------------------------- ---------------------- ----------------------- ---------------------- ---------
  Tumor stage                                                                                                                                         
    T3 and T4 vs. T1 and T2                                                     1.888 (1.022--3.488)   0.042                   1.903 (1.033--3.508)   0.039
  Histology                                                                                                                                           
    Poorly differentiated and mucinous vs. well and moderately differentiated   1.647 (0.906--2.995)   0.102                   1.409 (0.768--2.586)   0.268
  Lymphovascular invasion                                                       1.615 (0.992--2.629)   0.054                   1.593 (0.980--2.591)   0.061
  Programmed death-ligand 1 expression                                                                                                                
    Low vs. high                                                                1.274 (0.852--1.904)   0.238                   1.586 (1.069--2.353)   0.022
  Nodal stage                                                                                                                                         
    Positive vs. ≤ negative                                                     1.306 (0.829--2.056)   0.249                   1.430 (0.912--2.243)   0.119
  Perinodal extension                                                                                                                                 
    Positive vs. ≤ negative                                                     2.927 (1.693--5.060)   \<0.001                 3.057 (1.776--5.259)   \<0.001

HR, hazard ratio; CI, confidence interval.
